Ring Therapeutics

About Ring Therapeutics

Ring Therapeutics is focused on revolutionizing programmable medicines through its Anellogy™ platform, which harnesses the natural human commensal virome to develop viral-based therapies that safely and effectively deliver treatments to target cells and tissues.

Products & Services

Anellogy™ Platform:A revolutionary platform that transforms commensal viruses into therapies capable of delivering diverse therapeutic modalities to various tissues, leveraging unique properties like tissue tropism and immune evasion.

Specialties

Programmable genetic medicines Commensal virus-based therapies Anellovirus research and development Tissue and cellular tropism Immune system evasion in therapeutics

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series C T: - FT: Series C	A: 86500000 MR: - FA: 86.5 million FAN: 86500000	D: 2023-03-09 FD: 2023-03-09	10 investors

Series C Latest

2023-03-09

$86.5M

10 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

A

Avak Kahvejian

Founder, Ring Therapeutics; Partner, Flagship Pioneering

E

Erica Weinstein

N

Noubar Afeyan

C

Christopher McNulty

CEO

K

Konstantin Konstantinov

Chief Technology Officer

D

Dmitriy Bobrovnikov

Chief Innovation Officer

View 13 more team members with Pro

Unlock Full Team Directory

Recent News